AUTHOR=Peng Zhiyu , Ma Ruiqi , Zhang Yihan , Yan Mingxu , Lu Jie , Cheng Qian , Liao Jingjing , Zhang Yunqiu , Wang Jinghan , Zhao Yue , Zhu Jiang , Qin Bing , Jiang Qin , Shi Fei , Qian Jiang , Chen Xinjian , Zhao Chen TITLE=Development and evaluation of multimodal AI for diagnosis and triage of ophthalmic diseases using ChatGPT and anterior segment images: protocol for a two-stage cross-sectional study JOURNAL=Frontiers in Artificial Intelligence VOLUME=6 YEAR=2023 URL=https://www.frontiersin.org/journals/artificial-intelligence/articles/10.3389/frai.2023.1323924 DOI=10.3389/frai.2023.1323924 ISSN=2624-8212 ABSTRACT=Introduction

Artificial intelligence (AI) technology has made rapid progress for disease diagnosis and triage. In the field of ophthalmic diseases, image-based diagnosis has achieved high accuracy but still encounters limitations due to the lack of medical history. The emergence of ChatGPT enables human-computer interaction, allowing for the development of a multimodal AI system that integrates interactive text and image information.

Objective

To develop a multimodal AI system using ChatGPT and anterior segment images for diagnosing and triaging ophthalmic diseases. To assess the AI system's performance through a two-stage cross-sectional study, starting with silent evaluation and followed by early clinical evaluation in outpatient clinics.

Methods and analysis

Our study will be conducted across three distinct centers in Shanghai, Nanjing, and Suqian. The development of the smartphone-based multimodal AI system will take place in Shanghai with the goal of achieving ≥90% sensitivity and ≥95% specificity for diagnosing and triaging ophthalmic diseases. The first stage of the cross-sectional study will explore the system's performance in Shanghai's outpatient clinics. Medical histories will be collected without patient interaction, and anterior segment images will be captured using slit lamp equipment. This stage aims for ≥85% sensitivity and ≥95% specificity with a sample size of 100 patients. The second stage will take place at three locations, with Shanghai serving as the internal validation dataset, and Nanjing and Suqian as the external validation dataset. Medical history will be collected through patient interviews, and anterior segment images will be captured via smartphone devices. An expert panel will establish reference standards and assess AI accuracy for diagnosis and triage throughout all stages. A one-vs.-rest strategy will be used for data analysis, and a post-hoc power calculation will be performed to evaluate the impact of disease types on AI performance.

Discussion

Our study may provide a user-friendly smartphone-based multimodal AI system for diagnosis and triage of ophthalmic diseases. This innovative system may support early detection of ocular abnormalities, facilitate establishment of a tiered healthcare system, and reduce the burdens on tertiary facilities.

Trial registration

The study was registered in ClinicalTrials.gov on June 25th, 2023 (NCT 05930444).